Dogra J, Saxena V N
C.G.H.S. Jaipur, India.
Int J Parasitol. 1996 Dec;26(12):1413-5. doi: 10.1016/s0020-7519(96)00128-2.
Cutaneous leishmaniasis (CL) is a vector-borne parasitic disease of the skin. Previous open controlled studies with oral itraconazole suggest that it was effective for CL in India. Twenty patients with localised CL participated in this trial. Patients were allocated randomly to receive capsule itraconazole and matching placebo for 6 weeks. No topical medicines were used. Demonstration of Leishmania by slit smear was mandatory. Prior to, periodically during and 3 months after completion of therapy an overall clinical assessment, liver function tests and urinalysis were performed. On decoding, out of the 10 cases receiving drug itraconazole, 7 were declared cured by clinical and parasitological criteria. No major side-effects were noted. Spontaneous remission was observed in 1 case in the placebo group at 3 months follow up. Oral itraconazole has a promising antileishmanial thus secure CL patient from the hazards of antimonials.
皮肤利什曼病（CL）是一种由媒介传播的皮肤寄生虫病。先前关于口服伊曲康唑的开放性对照研究表明，它对印度的皮肤利什曼病有效。20名局限性皮肤利什曼病患者参与了该试验。患者被随机分配接受伊曲康唑胶囊和匹配的安慰剂，为期6周。未使用局部用药。通过涂片检查证实利什曼原虫是必需的。在治疗前、治疗期间定期以及治疗完成后3个月进行全面临床评估、肝功能检查和尿液分析。解密后，在接受伊曲康唑治疗的10例病例中，7例根据临床和寄生虫学标准被宣布治愈。未观察到重大副作用。在安慰剂组的1例患者中，随访3个月时观察到自发缓解。口服伊曲康唑具有有前景的抗利什曼原虫作用，从而使皮肤利什曼病患者免受锑剂的危害。
